

# Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Aleksandr Lazaryan,<sup>1</sup> Michelle Dolan,<sup>2</sup> Mei-Jie Zhang,<sup>3,4</sup> Hai-Lin Wang,<sup>3</sup> Mohamed A. Kharfan-Dabaja,<sup>5</sup> David I. Marks,<sup>6</sup> Nelli Bejanyan,<sup>7</sup> Edward Copelan,<sup>8</sup> Navneet S. Majhail,<sup>9</sup> Edmund K. Waller,<sup>10</sup> Nelson Chao,<sup>11</sup> Tim Prestidge,<sup>12</sup> Taiga Nishihori,<sup>13</sup> Partow Kebriaei,<sup>14</sup> Yoshihiro Inamoto,<sup>15</sup> Betty Hamilton,<sup>16</sup> Shahrukh K. Hashmi,<sup>17,18</sup> Rammurti T. Kamble,<sup>19</sup> Ulrike Bacher,<sup>20</sup> Gerhard C. Hildebrandt,<sup>21</sup> Patrick J. Stiff,<sup>22</sup> Joseph McGuirk,<sup>23</sup> Ibrahim Aldoss,<sup>24</sup> Amer M. Beitinjaneh,<sup>25</sup> Lori Muffly,<sup>26</sup> Ravi Vij,<sup>27</sup> Richard F. Olsson,<sup>28,29</sup> Michael Byrne,<sup>30</sup> Kirk R. Schultz,<sup>31</sup> Mahmoud Aljurf,<sup>18</sup> Matthew Seftel,<sup>32</sup> Mary Lynn Savoie,<sup>33</sup> Bipin N. Savani,<sup>34</sup> Leo F. Verdonck,<sup>35</sup> Mitchell S. Cairo,<sup>36</sup> Nasheed Hossain,<sup>37</sup> Vijaya Raj Bhatt,<sup>38</sup> Haydar A. Frangoul,<sup>39</sup> Hisham Abdel-Azim,<sup>40</sup> Monzr Al Malki,<sup>24</sup> Reinhold Munker,<sup>41</sup> David Rizzieri,<sup>42</sup> Nandita Khera,<sup>43</sup> Ryotaro Nakamura,<sup>44</sup> Olle Ringdén,<sup>45</sup> Marjolein van der Poel,<sup>46</sup> Hemant S. Murthy,<sup>47</sup> Hongtao Liu,<sup>48</sup> Shahram Mori,<sup>49</sup> Satiro De Oliveira,<sup>50</sup> Javier Bolaños-Meade,<sup>51</sup> Mahmoud Elsayy,<sup>52</sup> Pere Barba,<sup>53</sup> Sunita Nathan,<sup>54</sup> Biju George,<sup>55</sup> Attaphol Pawarode,<sup>56</sup> Michael Grunwald,<sup>57</sup> Vaibhav Agrawal,<sup>58</sup> Youjin Wang,<sup>59</sup> Amer Assal,<sup>60</sup> Paul Castillo Caro,<sup>61</sup> Yachiyo Kuwatsuka,<sup>62</sup> Sachiko Seo,<sup>63</sup> Celalettin Ustun,<sup>64</sup> Ioannis Politikos,<sup>65</sup> Hillard M. Lazarus,<sup>66</sup> Wael Saber,<sup>3</sup> Brenda M. Sandmaier,<sup>67</sup> Marcos De Lima,<sup>68</sup> Mark Litzow,<sup>69</sup> Veronika Bachanova<sup>70</sup> and Daniel Weisdorf,<sup>71</sup> Acute Leukemia Committee of the CIBMTR<sup>3</sup>

<sup>1</sup>H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; <sup>2</sup>University of Minnesota Medical Center, Minneapolis, MN, USA; <sup>3</sup>CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA; <sup>4</sup>Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA; <sup>5</sup>Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA; <sup>6</sup>Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, UK; <sup>7</sup>Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA; <sup>8</sup>Levine Cancer Institute, Atrium Health, Carolinas HealthCare System, Charlotte, NC, USA; <sup>9</sup>Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; <sup>10</sup>Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA; <sup>11</sup>Division of Cell Therapy and Hematology, Department of Medicine, Duke University Medical Center, Durham, NC, USA; <sup>12</sup>Blood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand; <sup>13</sup>Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; <sup>14</sup>Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, TX, USA; <sup>15</sup>Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan; <sup>16</sup>Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; <sup>17</sup>Department of Internal Medicine, Mayo Clinic, MN, USA; <sup>18</sup>Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; <sup>19</sup>Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA; <sup>20</sup>Department of Hematology, Inselspital, Bern University Hospital, Switzerland; <sup>21</sup>Markey Cancer Center, University of Kentucky, Lexington, KY, USA; <sup>22</sup>Loyola University Medical Center, Maywood, IL, USA; <sup>23</sup>University of Kansas Medical Center, Westwood, KS, USA; <sup>24</sup>City of Hope Comprehensive Cancer Center, Duarte, CA, USA; <sup>25</sup>University of Miami, Miami, FL, USA; <sup>26</sup>Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA, USA; <sup>27</sup>Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO, USA; <sup>28</sup>Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; <sup>29</sup>Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden; <sup>30</sup>Vanderbilt University Medical Center, Nashville, TN, USA; <sup>31</sup>Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia's Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada; <sup>32</sup>Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, Manitoba, Canada; <sup>33</sup>Tom Baker Cancer Centre, Calgary, Alberta, Canada; <sup>34</sup>Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; <sup>35</sup>Department of Hematology/Oncology, Isala Clinic, Zwolle, the Netherlands; <sup>36</sup>Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, NY, USA; <sup>37</sup>Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA; <sup>38</sup>The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA; <sup>39</sup>The Children's Hospital at TriStar Centennial and Sarah Cannon Research Institute, Nashville, TN, USA; <sup>40</sup>Division of Hematology, Oncology and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA; <sup>41</sup>Section of Hematology/Oncology, Department of Internal Medicine, Louisiana State University Health Shreveport, Shreveport, LA, USA; <sup>42</sup>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA; <sup>43</sup>Department of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA; <sup>44</sup>Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA; <sup>45</sup>Translational Cell Therapy Group, CLINTEC (Clinical Science, Intervention and Technology), Karolinska Institutet, Stockholm Sweden; <sup>46</sup>Academische Ziekenhuis Maastricht, Maastricht, the Netherlands; <sup>47</sup>Mayo Clinic Florida, Jacksonville, FL, USA; <sup>48</sup>University of Chicago Medicine, Chicago, IL, USA; <sup>49</sup>Blood & Marrow Transplant Center, Florida Hospital Medical Group, Orlando, FL, USA; <sup>50</sup>UCLA Medical Center, Los Angeles, CA, USA; <sup>51</sup>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA; <sup>52</sup>QE II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada; <sup>53</sup>Hospital Vall d'Hebron, Barcelona, Spain; <sup>54</sup>Rush University Medical Center, Chicago, IL, USA; <sup>55</sup>Christian Medical College, Vellore, India; <sup>56</sup>Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI, USA; <sup>57</sup>Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA; <sup>58</sup>Division of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, IN, USA; <sup>59</sup>National Cancer Institute (NCI), Rockville, MD, USA; <sup>60</sup>New York Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA; <sup>61</sup>UF Health Shands Children's Hospital, Gainesville, FL, USA; <sup>62</sup>Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan; <sup>63</sup>Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan; <sup>64</sup>Division of Hematology/Oncology/Cell Therapy, Rush University, Chicago, IL, USA; <sup>65</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>66</sup>Case Western Reserve University, Cleveland, OH, USA; <sup>67</sup>Division of Medical Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; <sup>68</sup>Department of Medicine, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA; <sup>69</sup>Division of

Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, MN, USA; <sup>70</sup>Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN, USA and <sup>71</sup>Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN, USA.

Published in *Haematologica* 2020;105(5):1329-1338

doi:10.3324/haematol.2021.279046

©2021 Ferrata Storti Foundation

The authors inadvertently included grant numbers OT3HL147741 & U24CA233032, which are grant-specific. This was an oversight on the authors' part as these grants did not support the research in this publication.

### **An incorrect version of “acknowledgments” appeared in the May 2020 issue on page 1337.**

#### **Acknowledgments**

The CIBMTR is supported primarily by a public health service grant/cooperative agreement U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); grant/cooperative agreement U24HL138660 from the NHLBI and NCI; grant U24CA233032 from the NCI; grants OT3HL147741, R21HL140314 and U01HL128568 from the NHLBI; a contract HSH250201700006C with Health Resources and Services Administration (HRSA/DHHS); grants N00014-18-1-2888 and N00014-17-1-2850 from the Office of Naval Research; and grants from \*Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies; \*Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; \*Anthem, Inc.; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; \*bluebird bio, Inc.; Boston Children's Hospital; \*Bristol Myers Squibb Co.; \*Celgene Corp.; Children's Hospital of Los Angeles; \*Chimerix, Inc.; \*CSL Behring; \*CytoSen Therapeutics, Inc.; Dana Farber Cancer Institute; \*Daiichi Sankyo Co., Ltd.; Fred Hutchinson Cancer Research Center; \*Gamida-Cell, Ltd.; Gilead Sciences, Inc.; \*GlaxoSmithKline (GSK); HistoGenetics, Inc.; Immucor; Incyte Corporation; Janssen Biotech, Inc.; \*Janssen Pharmaceuticals, Inc.; Janssen Scientific Affairs, LLC; \*Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.; \*Kite, a Gilead Company; \*Magenta Therapeutics; Medac GmbH; The Medical College of Wisconsin; Mediware; Merck & Company, Inc.; \*Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; \*Miltenyi Biotec, Inc.; Mundipharma EDO; National Marrow Donor Program; Novartis Oncology; Novartis Pharmaceuticals Corporation; \*Omeros Corporation; \*Oncoimmune, Inc.; PCORI; \*Pfizer, Inc.; \*Pharmacyclics, LLC; PIRCHE AG; \*Regeneron Pharmaceuticals, Inc.; REGiMMUNE Corp.; \*Sanofi Genzyme; \*Seattle Genetics; \*Shire; Sobi, Inc.; Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; Swedish Orphan Biovitrum, Inc.; \*Takeda Oncology; University of Minnesota; University of Pittsburgh; University of Texas-MD Anderson; University of Wisconsin – Madison and Viracor Eurofins. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. \*Corporate Members.

### **The correct version of “acknowledgments” is published on this page.**

#### **Acknowledgments**

The CIBMTR is supported primarily by a public health service grant/cooperative agreement U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); grant/cooperative agreement U24HL138660 from the NHLBI and NCI; grants R21HL140314 and U01HL128568 from the NHLBI; a contract HSH250201700006C with Health Resources and Services Administration (HRSA/DHHS); grants N00014-18-1-2888 and N00014-17-1-2850 from the Office of Naval Research; and grants from \*Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies; \*Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; \*Anthem, Inc.; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; \*bluebird bio, Inc.; Boston Children's Hospital; \*Bristol Myers Squibb Co.; \*Celgene Corp.; Children's Hospital of Los Angeles; \*Chimerix, Inc.; \*CSL Behring; \*CytoSen Therapeutics, Inc.; Dana Farber Cancer Institute; \*Daiichi Sankyo Co., Ltd.; Fred Hutchinson Cancer Research Center; \*Gamida-Cell, Ltd.; Gilead Sciences, Inc.; \*GlaxoSmithKline (GSK); HistoGenetics, Inc.; Immucor; Incyte Corporation; Janssen Biotech, Inc.; \*Janssen Pharmaceuticals, Inc.; Janssen Scientific Affairs, LLC; \*Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.; \*Kite, a Gilead Company; \*Magenta Therapeutics; Medac GmbH; The Medical College of Wisconsin; Mediware; Merck & Company, Inc.; \*Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; \*Miltenyi Biotec, Inc.; Mundipharma EDO; National Marrow Donor Program; Novartis Oncology; Novartis Pharmaceuticals Corporation; \*Omeros Corporation; \*Oncoimmune, Inc.; PCORI; \*Pfizer, Inc.; \*Pharmacyclics, LLC; PIRCHE AG; \*Regeneron Pharmaceuticals, Inc.; REGiMMUNE Corp.; \*Sanofi Genzyme; \*Seattle Genetics; \*Shire; Sobi, Inc.; Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; Swedish Orphan Biovitrum, Inc.; \*Takeda Oncology; University of Minnesota; University of Pittsburgh; University of Texas-MD Anderson; University of Wisconsin – Madison and Viracor Eurofins. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. \*Corporate Members.